Advocate

Country: European Union

Language: Swedish

Source: EMA (European Medicines Agency)

Active ingredient:

imidakloprid, moxidektin

Available from:

Bayer Animal Health GmbH

ATC code:

QP54AB52

INN (International Name):

imidacloprid, moxidectin

Therapeutic group:

Dogs; Cats; Ferrets

Therapeutic area:

Antiparasitiska produkter, insekticider och repellenter

Therapeutic indications:

DogsFor hundar som lider av, eller riskerar, blandade parasitinfektioner:förebyggande och behandling av loppangrepp (Ctenocephalides felis),behandling av bitande löss (Trichodectes canis),behandling av örat kvalster angrepp (Otodectes cynotis), sarcoptic mange (orsakad av Sarcoptes scabiei var. canis), demodicosis (orsakad av Demodex canis),förebyggande av hjärtmask sjukdom (L3 och L4 larver av Dirofilaria immitis),behandling av cirkulerande microfilariae (Dirofilaria immitis),behandling av kutan dirofilariosis (vuxna stadier av Dirofilaria repens)förebyggande av kutan dirofilariosis (L3 larver av Dirofilaria repens),minskning av cirkulerande microfilariae (Dirofilaria repens),förebyggande av angiostrongylosis (L4 larver och omogna vuxna av Angiostrongylus vasorum),behandling av Angiostrongylus vasorum och Crenosoma vulpis,förebyggande av spirocercosis (Spirocerca lupi),behandling av Eucoleus (syn. Capillaria) boehmi (vuxna),behandling av eye mask Thelazia callipaeda (vuxna),behandling av infektioner med gastrointestinala nematoder (L4 larver, omogna vuxna och vuxna av Toxocara canis, Ancylostoma caninum och Uncinaria stenocephala, vuxna av Toxascaris leonina och Trichuris vulpis). Produkten kan användas som en del av en behandlingsstrategi för lopporallergi-dermatit (FAD). CatsFor katter som lider av, eller riskerar, blandade parasitinfektioner:förebyggande och behandling av loppangrepp (Ctenocephalides felis),behandling av örat kvalster angrepp (Otodectes cynotis),behandling av notoedric mange (Notoedres cati),behandling av lungworm Eucoleus aerophilus (syn. Capillaria aerophila) (vuxna),förebyggande av lungworm sjukdom (L3/L4 larver av Aelurostrongylus abstrusus),behandling av lungworm Aelurostrongylus abstrusus (vuxna),behandling av eye mask Thelazia callipaeda (vuxna),förebyggande av hjärtmask sjukdom (L3 och L4 larver av Dirofilaria immitis),behandling av infektioner med gastrointestinala nematoder (L4 larver, omogna vuxna och vuxna av Toxocara cati och Ancylostoma tubaeforme). Produkten kan användas som en del av en behandlingsstrategi för lopporallergi-dermatit (FAD). FerretsFor illrar som lider av, eller riskerar, blandade parasitinfektioner:förebyggande och behandling av loppangrepp (Ctenocephalides felis),förebyggande av hjärtmask sjukdom (L3 och L4 larver av Dirofilaria immitis).

Product summary:

Revision: 23

Authorization status:

auktoriserad

Authorization date:

2003-04-02

Patient Information leaflet

                                OFFICIAL ADDRESS
Domenico Scarlattilaan 6
●
1083 HS Amsterdam
●
The Netherlands
An agency of the European Union
ADDRESS FOR VISITS AND DELIVERIES
Refer to www.ema.europa.eu/how-to-find-us
SEND US A QUESTION
Go to
www.ema.europa.eu/contact
TELEPHONE
+31 (0)88 781
6000
© European Medicines Agency,
2023. Reproduction is authorised provided the source is acknowledged.
Aktuell information om detta veterinärmedicinska läkemedel finns på
webbplatsen för
veterinärmedicinsk information.
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                OFFICIAL ADDRESS
Domenico Scarlattilaan 6
●
1083 HS Amsterdam
●
The Netherlands
An agency of the European Union
ADDRESS FOR VISITS AND DELIVERIES
Refer to www.ema.europa.eu/how-to-find-us
SEND US A QUESTION
Go to
www.ema.europa.eu/contact
TELEPHONE
+31 (0)88 781
6000
© European Medicines Agency,
2023. Reproduction is authorised provided the source is acknowledged.
Aktuell information om detta veterinärmedicinska läkemedel finns på
webbplatsen för
veterinärmedicinsk information.
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 31-01-2024
Public Assessment Report Public Assessment Report Bulgarian 29-01-2024
Patient Information leaflet Patient Information leaflet Spanish 31-01-2024
Public Assessment Report Public Assessment Report Spanish 29-01-2024
Patient Information leaflet Patient Information leaflet Czech 31-01-2024
Public Assessment Report Public Assessment Report Czech 29-01-2024
Patient Information leaflet Patient Information leaflet Danish 31-01-2024
Public Assessment Report Public Assessment Report Danish 29-01-2024
Patient Information leaflet Patient Information leaflet German 31-01-2024
Public Assessment Report Public Assessment Report German 29-01-2024
Patient Information leaflet Patient Information leaflet Estonian 31-01-2024
Public Assessment Report Public Assessment Report Estonian 29-01-2024
Patient Information leaflet Patient Information leaflet Greek 31-01-2024
Public Assessment Report Public Assessment Report Greek 29-01-2024
Patient Information leaflet Patient Information leaflet English 31-01-2024
Public Assessment Report Public Assessment Report English 29-01-2024
Patient Information leaflet Patient Information leaflet French 31-01-2024
Public Assessment Report Public Assessment Report French 29-01-2024
Patient Information leaflet Patient Information leaflet Italian 31-01-2024
Public Assessment Report Public Assessment Report Italian 29-01-2024
Patient Information leaflet Patient Information leaflet Latvian 31-01-2024
Public Assessment Report Public Assessment Report Latvian 29-01-2024
Patient Information leaflet Patient Information leaflet Lithuanian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 31-01-2024
Public Assessment Report Public Assessment Report Lithuanian 29-01-2024
Patient Information leaflet Patient Information leaflet Hungarian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 31-01-2024
Public Assessment Report Public Assessment Report Hungarian 29-01-2024
Patient Information leaflet Patient Information leaflet Maltese 31-01-2024
Public Assessment Report Public Assessment Report Maltese 29-01-2024
Patient Information leaflet Patient Information leaflet Dutch 31-01-2024
Public Assessment Report Public Assessment Report Dutch 29-01-2024
Patient Information leaflet Patient Information leaflet Polish 31-01-2024
Public Assessment Report Public Assessment Report Polish 29-01-2024
Patient Information leaflet Patient Information leaflet Portuguese 31-01-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 31-01-2024
Public Assessment Report Public Assessment Report Portuguese 29-01-2024
Patient Information leaflet Patient Information leaflet Romanian 31-01-2024
Public Assessment Report Public Assessment Report Romanian 29-01-2024
Patient Information leaflet Patient Information leaflet Slovak 31-01-2024
Public Assessment Report Public Assessment Report Slovak 29-01-2024
Patient Information leaflet Patient Information leaflet Slovenian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 31-01-2024
Public Assessment Report Public Assessment Report Slovenian 29-01-2024
Patient Information leaflet Patient Information leaflet Finnish 31-01-2024
Public Assessment Report Public Assessment Report Finnish 29-01-2024
Patient Information leaflet Patient Information leaflet Norwegian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 31-01-2024
Public Assessment Report Public Assessment Report Norwegian 29-01-2024
Patient Information leaflet Patient Information leaflet Icelandic 31-01-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 31-01-2024
Public Assessment Report Public Assessment Report Icelandic 29-01-2024
Patient Information leaflet Patient Information leaflet Croatian 31-01-2024
Public Assessment Report Public Assessment Report Croatian 29-01-2024

View documents history